CAB 91: Meeting with MSD; re-engagement to care; CHANGE meetings update
Date: Friday 20 June 2025
Venue: Room G16, Birkbeck University London, WC1E 7HX
Programme:
| Chair: John Jaquiss | |
| 09.30-09.45 | Arrival, tea and refreshments, expenses |
| 09:45- 10.00 | Welcome and introductions – John Jaquiss MSD pre-meeting – Ben Cromarty, UK-CAB |
| 10:00-11.00 | MSD updates – Dr Alastair Teague, Central and North West London NHS Foundation |
| 11:00-11:40 | *MSD’s elimination strategy experience: Learnings to support the Government’s goal of zero new HIV transmissions by 2030 – MSD |
| 11.40-11.45 | BREAK |
| 11.45-12.45 | Disengangement from care – the next big challenge – Dr Kate Childs, Kings College London |
| 13:00-14.00 | LUNCH |
| 14:00-15:00 | Re-engagement to care – Clara Marukutira, THT |
| 15.00-15.15 | BREAK |
| 15.15-16.00 | CHANGE meetings update – Paul Clift, UK-CAB |
| 16:00 -16:30 | ABPI update – Harun Tulunay |
| 16.30 – 17:00 | Member updates Meeting reflection Any other business Meeting close |
| *Disclaimer: MSD has sponsored the UK Community Advisory Board (UK-CAB) programme for 2025, and therefore this meeting has been partially funded by MSD. MSD have had no input into the content or agenda of this or any meetings, except the agenda item titled “MSD’s elimination strategy experience: Learnings to support the Government’s goal of zero new HIV transmissions by 2030. | |
Slides from meeting
MSD pre-meeting (confidential) – Ben Cromarty
MSD updates (confidential)- Dr Alastair Teague
MSD’s elimination strategy experience: Learnings to support the Government’s goal of zero new HIV transmissions by 2030
Disengagement from care – the next big challenge – Dr Kate Childs
Re-engangement into care – Clara Marukutira
CHANGE meetings updates – Paul Clift
ABPI update – Harun Tulunay
Background reading:
- Switching to daily fixed-dose doravirine/islatravir: two randomised phase 3 studies
- ART pipeline 2025: exciting dual long-acting combinations and the challenge of generic dolutegravir
- Islatravir update: treatment studies to use a lower dose but PrEP research discontinued in favour of MK-8537
UK-CAB funding
The administration of the UK-CAB is through Positively UK. The costs for UK-CAB meetings are covered by support from pharmaceutical companies (see details below).
Funding by pharmaceutical companies
We ask pharmaceutical companies that have current HIV drugs to help fund the UK-CAB and the quarterly training meetings.
The funding covers the project administration, travel and accommodation for members attending from out of London, as well as the cost of catering for the four meetings. This funding helps support the UK-CAB as a national project. A list of supporting companies since the UK-CAB was established in 2002 and from the most recent two years is included below. [3]
The UK-CAB membership and the Steering Group decide the content and agendas for the programme of meetings. When the UK-CAB meets with pharmaceutical companies about their current products and future research, the decisions for which companies to invite and the agenda for these meetings is made by the UK-CAB.
We similarly ask independent researchers to actively involve the UK-CAB in planning studies and ongoing research. We ask that community involvement in research be included in the budget of grant proposals so that some of the UK-CAB work can be supported in this way by independent research.
Notes
- Directors and employees of pharmaceutical companies involved in research into HIV treatment and diagnostics, or employees of agencies providing PR, marketing and other professional services for these companies may not join the UK-CAB. We work closely with industry, but the UK-CAB is a community-based network, and it is important to respect this boundary.
- UK-CAB cannot provide any funding for people travelling from outside England, Wales, Scotland, Northern Ireland, Isle of Man or the Channel Islands.
- Since 2002, the UK-CAB has received support towards meeting costs from the following pharmaceutical companies: Abbott Laboratories, AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb (BMS), Gilead Sciences, GlaxoSmithKline (GSK), Janssen-Cilag, Koronis, Merck Sharp and Dohme (MSD), Roche Laboratories, Theratechnologies, Tibotec, Pfizer, ViiV Healthcare. Since April 2012, the UK-CAB has been supported by Abbott Laboratories, AbbVie, Bristol-Myers Squibb (BMS), Gilead Sciences, Janssen-Cilag, Merck Sharp and Dohme (MSD) and ViiV Healthcare. This funding is unconnected to the programme and content of meetings.